<DOC>
	<DOCNO>NCT02200575</DOCNO>
	<brief_summary>Study confirm safety profile telmisartan ( benefit-risk ratio ) normal condition use market launch supplement present data safety telmisartan . Furthermore assess effectiveness single dose telmisartan per day control blood pressure 24 hour , especially last hour dosage interval . Additionally evaluate compliance treatment , indirect measurement , confirm efficacy possible risk associate treatment .</brief_summary>
	<brief_title>Pharmacovigilance Patient Compliance Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Patients either sex age 18 year suffer nonsecondary essential hypertension value least 90 mmHg ( diastolic ) 140 mmHg ( systolic ) correspond contraindication list summary product characteristic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>